Display options
Cite
Singh RD, Haridas N, Patel JB, et al. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem. 2010;25(3):250-9doi: 10.1007/s12291-010-0060-8.
Singh, R. D., Haridas, N., Patel, J. B., Shah, F. D., Shukla, S. N., Shah, P. M., & Patel, P. S. (2010). Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian journal of clinical biochemistry : IJCB, 25(3), 250-9. https://doi.org/10.1007/s12291-010-0060-8
Singh, Ragini D, et al. "Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer." Indian journal of clinical biochemistry : IJCB vol. 25,3 (2010): 250-9. doi: https://doi.org/10.1007/s12291-010-0060-8
Singh RD, Haridas N, Patel JB, Shah FD, Shukla SN, Shah PM, Patel PS. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem. 2010 Jul;25(3):250-9. doi: 10.1007/s12291-010-0060-8. Epub 2010 Aug 25. PMID: 21731196; PMCID: PMC3001841.
Copy Download .nbib Format: NLM
Share it on

Indian J Clin Biochem. 2010 Jul;25(3):250-9. doi: 10.1007/s12291-010-0060-8. Epub 2010 Aug 25.

Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer.

Indian journal of clinical biochemistry : IJCB

Ragini D Singh, N Haridas, Jayendra B Patel, Franky D Shah, Shilin N Shukla, Pankaj M Shah, Prabhudas S Patel

PMID: 21731196 PMCID: PMC3001841 DOI: 10.1007/s12291-010-0060-8

Abstract

Matrix metalloproteinases (MMPs) have been implicated in invasion and metastasis of various malignancies. The study evaluated a comprehensive profile of MMP-2 and MMP-9 and their inhibitors, tissue inhibitor of metalloproteinases-2 (TIMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1), respectively in 50 controls and 75 patients with oral squamous cell carcinoma (OSCC). Blood samples from controls and patients as well as malignant and adjacent normal tissues from the patients were collected. The study examined pro, active and total forms of MMP-2 and MMP-9 using zymography. Enzyme-linked immunoassay (ELISA) and reverse transcription polymerase chain reaction were carried out to evaluate protein levels and mRNA expression; respectively, for the MMPs and TIMPs. Plasma pro, active and total MMP-2, MMP-9 as well as TIMP-1 and TIMP-2 levels were significantly higher in oral cancer patients as compared to the controls. mRNA expression of the MMPs and TIMPs was significantly higher in malignant tissues as compared to adjacent normal tissues. A significant positive correlation was observed between levels of proMMP-9 and active MMP-9 with differentiation, stage and infiltration. ProMMP-2 and active MMP-2 exhibited significant positive correlation with differentiation and lymph node involvement. The multivariate analysis of ELISA results revealed a significant positive correlation between MMP-2, TIMP-1 and TIMP-2 levels with lymph node involvement, stage and differentiation. The receiver operating characteristic curve (ROC) analysis showed that the levels of MMPs and TIMPs have significant discriminatory efficacy to differentiate between controls and patients. The results indicate that MMP-2, MMP-9, TIMP-1 and TIMP-2 have significant clinical usefulness for oral cancer patients. Zymographic analysis is a simple, cost effective, rapid and sensitive alternative assay.

Keywords: Invasion; MMPs; Metastasis; Oral cancer; TIMPs; Zymography

References

  1. Indian J Cancer. 2009 Jul-Sep;46(3):194-202 - PubMed
  2. Br J Cancer. 2004 Apr 5;90(7):1414-21 - PubMed
  3. Cancer. 2002 Mar 1;94(5):1483-91 - PubMed
  4. Br J Cancer. 1998 Jun;77(12):2239-45 - PubMed
  5. Bull World Health Organ. 2009 Mar;87(3):200-6 - PubMed
  6. Oral Oncol. 1999 May;35(3):227-33 - PubMed
  7. Cancer Lett. 2000 Mar 13;150(1):15-21 - PubMed
  8. Int J Cancer. 2000 May 1;86(3):307-17 - PubMed
  9. Clin Exp Metastasis. 1999 Jun;17(4):315-23 - PubMed
  10. Oral Oncol. 2009 Aug;45(8):647-53 - PubMed
  11. J Surg Oncol. 2005 May 1;90(2):81-8 - PubMed
  12. Oral Oncol. 2005 Mar;41(3):283-93 - PubMed
  13. Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 - PubMed
  14. Clin Cancer Res. 2004 May 1;10(9):3110-6 - PubMed
  15. Int J Oncol. 1998 Oct;13(4):699-704 - PubMed
  16. Anticancer Res. 2002 Jul-Aug;22(4):2221-7 - PubMed
  17. Nat Rev Cancer. 2006 Mar;6(3):227-39 - PubMed
  18. Ann Otol Rhinol Laryngol. 1995 Sep;104(9 Pt 1):678-84 - PubMed
  19. Biochimie. 2005 Mar-Apr;87(3-4):287-97 - PubMed
  20. Head Neck. 1999 Oct;21(7):627-38 - PubMed
  21. Oral Oncol. 2000 Mar;36(2):207-13 - PubMed
  22. Pathol Res Pract. 2002;198(8):509-15 - PubMed
  23. Ann Otol Rhinol Laryngol. 1997 Apr;106(4):271-8 - PubMed
  24. Oral Oncol. 2008 May;44(5):446-54 - PubMed
  25. J Clin Oncol. 2000 Mar;18(5):1135-49 - PubMed
  26. BMC Urol. 2006 Aug 10;6:19 - PubMed
  27. Anticancer Res. 2000 Sep-Oct;20(5A):3045-9 - PubMed
  28. Int J Cancer. 2001 Jan 20;95(1):44-50 - PubMed
  29. Oncol Rep. 2009 May;21(5):1323-33 - PubMed
  30. Matrix. 1992 Aug;12(4):282-90 - PubMed

Publication Types